5.4.9Segment

Pharmaceutical & Drug Distribution

Drug wholesale distributors and specialty pharmaceutical distributors supplying medications to hospitals, pharmacies, and clinics.

5
Verticals

Overview

Pharmaceutical & Drug Distribution covers the wholesalers that move prescription drugs from manufacturers to pharmacies, hospitals, and providers. At ~$1.28 trillion in sales it is the second-largest distribution segment and one of the most concentrated industries in the economy — an effective oligopoly of McKesson, Cencora (AmerisourceBergen), and Cardinal Health controlling the vast majority of volume.

It is an extreme high-volume, razor-thin-margin business (often ~1–2% gross), where scale, logistics precision, and manufacturer/payer relationships are everything. Specialty-pharmaceutical distribution (high-cost biologics, cold-chain) is the higher-margin growth area; the segment is mature and highly consolidated.

Market snapshot

Market size
~$1.28T
Growth
~6.6%CAGR (2017–22, nominal)
Companies
~7,012 firms
Firms by employee count

81.7% of firms have fewer than 20 employees: 5,729 micro-businesses, below most mandates.

The investable universe1,283 firms with 20+ employees
20–99
79862%
100–499
27421%
500+
21116%

The most consolidated channel in American distribution — three companies move the overwhelming majority of pharmaceuticals, on gross margins around two percent. The revenue figure is therefore close to meaningless as a market opportunity; what is acquirable sits in specialty, compounding and long-term-care pharmacy distribution, not in the mainline channel.

NAICS 424210. U.S. Census Bureau — 2022 Statistics of U.S. Businesses; U.S. Census Bureau — 2022 Economic Census.

Business model & economics

Revenue model

Drug resale at very thin margins on enormous volume

Key economics

Revenue per firm
$182,678,078
Revenue per employee
$4,158,014
Employees per firm
44.4
Recurring revenue
High

recurring pharmacy/provider supply

EBITDA margin
Very thin

~1–2% gross distribution margins

Capex intensity
Low

Characteristics

  • Scale-driven — payroll is only 3% of revenue; the cost base is assets, not headcount
  • Deep strategic-buyer pool — 211 firms exceed 500 employees, so a scaled asset has trade buyers
  • An oligopoly of McKesson, Cencora, and Cardinal.
  • Razor-thin margins on enormous volume.
  • Specialty-pharma distribution the higher-margin growth area.

NAICS 424210. U.S. Census Bureau — 2022 Statistics of U.S. Businesses; U.S. Census Bureau — 2022 Economic Census.

Geographic concentration

AlabamaAlaskaArizonaColoradoFloridaGeorgiaIndianaKansasMaineMassachusettsMinnesotaNorth CarolinaNorth DakotaOklahomaPennsylvaniaSouth DakotaTexasWyomingConnecticutMissouriWest VirginiaIllinoisNew MexicoArkansasDelawareDistrict of ColumbiaHawaiiIowaKentuckyMarylandMichiganMississippiMontanaNew HampshireOhioOregonTennesseeUtahVirginiaWashingtonWisconsinNebraskaSouth CarolinaIdahoVermontLouisianaRhode IslandNew JerseyCaliforniaNew YorkNevada

New Jersey is more than twice as concentrated as the country, on the pharmaceutical corridor and the port that serves it; Nevada reflects national distribution centres placed for next-day reach rather than local demand.

New JerseyNevadaCaliforniaNew York

U.S. Census Bureau — 2022 Statistics of U.S. Businesses (firms by state), NAICS 424210. Concentration shown by location quotient.

M&A deal context

Deal activityModerate

Who’s acquiring

  • The big-three distribution strategics
  • Specialty-pharma distribution acquirers
  • Vertical (pharmacy/provider) integrators

What’s driving deals

  • Specialty and cold-chain pharma growth.
  • Vertical integration with pharmacy and providers.
  • Scale and logistics efficiency.

Verticals in this segment

Find Pharmaceutical & Drug Distribution acquisition targets

Search Acquisera’s index for companies classified under Pharmaceutical & Drug Distribution (5.4.9) and build a targeted deal pipeline.

Search companies